Provided by Tiger Trade Technology Pte. Ltd.

ProMIS Neurosciences Inc

15.25
+0.29001.94%
Volume:18.87K
Turnover:286.68K
Market Cap:32.82M
PE:-0.76
High:15.35
Open:15.29
Low:14.99
Close:14.96
52wk High:39.75
52wk Low:6.27
Shares:2.15M
Float Shares:1.02M
Volume Ratio:0.46
T/O Rate:1.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-20.0495
EPS(LYR):2.68
ROE:-355.80%
ROA:-85.38%
PB:3.57
PE(LYR):5.69

Loading ...

ProMIS Neurosciences Is Maintained at Buy by Guggenheim

Dow Jones
·
Feb 06

ABG Management Ltd. Reports Acquisition of ProMIS Neurosciences Common Shares

Reuters
·
Feb 06

ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

GlobeNewswire
·
Feb 05

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:09 AM

Reuters
·
Jan 30

Promis Neurosciences Inc trading halted, volatility trading pause

TIPRANKS
·
Jan 30

ProMIS Neurosciences : Proceeds Expected to Enable Completion of ProMIS' Landmark Phase 1B Ad Study and Support Execution of Key Clinical Milestones

THOMSON REUTERS
·
Jan 30

ProMIS Neurosciences Inc: Extends Cash Runway Into 2028

THOMSON REUTERS
·
Jan 30

ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

GlobeNewswire
·
Jan 30

Fact Check: North Natuna Sea Was Not Used as Collateral for the Whoosh Rail Project

Tempo
·
Jan 16

BRIEF-Promis Neurosciences Exceeds Target Enrollment In Precise-Ad Phase 1B Cli Trial

Reuters
·
Dec 18, 2025

ProMIS Neurosciences Completes Enrollment for Phase 1b Trial of PMN310 in Alzheimer’s Disease

Reuters
·
Dec 18, 2025

ProMIS Neurosciences Inc - Interim Analysis Expected in Q2 2026, Final Results in Q4 2026

THOMSON REUTERS
·
Dec 18, 2025

ProMIS Neurosciences Exceeds Target Enrollment in Precise-Ad Phase 1B Clinical Trial of Pmn310 in Alzheimer’s Disease

THOMSON REUTERS
·
Dec 18, 2025

ProMIS Neurosciences Advances PMN310 Alzheimer’s Trial With Interim Results Expected in 2026

Reuters
·
Dec 10, 2025

ProMIS Neurosciences Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 02, 2025

BRIEF-Plasma pTau Identified as Key Early Endpoint in Alzheimer's Research

Reuters
·
Dec 01, 2025

ProMIS Neurosciences Announces Interim Phase 1b Trial Readout for PMN310 in Alzheimer's Disease Set for Q2 2026

Reuters
·
Dec 01, 2025

ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma Ptau as a Predictive Early Endpoint in Alzheimer’s Trials, Supporting Its Ongoing Phase 1B Precise-Ad Trial With Pmn310

THOMSON REUTERS
·
Dec 01, 2025

ProMIS Neurosciences CEO to Join Fireside Chat at Evercore Healthcare Conference

Reuters
·
Dec 01, 2025

NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM

Reuters
·
Nov 27, 2025